On this page
This entry or formulation may be investigational and may not correspond to an FDA-approved product; safety and efficacy may not have been established. Kairo lists it for identification and record-keeping only.
Overview
Product & regulatory status
Research analogue; this guide does not establish a therapeutic indication.
Binding proteins matter
LR3IGF-I has reduced affinity for IGF-binding proteins in the cited experiment. [1]
What the evidence shows
Animal glucose experiment
A comparative pig study found stronger and more sustained glucose lowering from LR3IGF-I than native IGF-I. This was pharmacology research, not a bodybuilding trial. [1]
What potency does not prove
The experiment does not demonstrate increased human strength or safe local muscle growth. Greater biological activity can also increase risk. [1]
What remains unknown
Human recovery outcomes, long-term safety, and a validated clinical exposure range remain unanswered by this evidence.
Safety
Glucose-lowering concern
The observed prolonged hypoglycemic action in animals is a reason for concern, not a safe human dosing guide. [1]
Exact identity
The experiment evaluated a particular analogue, not any product marketed with an IGF-1 label. [1]
Understanding product quality
Compounded drugs are not FDA-approved finished products. Poor preparation can cause contamination or incorrect strength. A catalog entry or a research paper is not a quality assessment of your product. [2]
When to seek urgent help
Severe allergic symptoms such as trouble breathing, throat or tongue swelling, or fainting need immediate help. Call 911 or your local emergency number. This is general emergency information, not a complete list of risks for this compound. [3]
A starting point for discussion
This is not a complete list of adverse effects or interactions. Your health history, other medicines, and the exact formulation matter. Missing safety data is not evidence of safety.
Common questions
Does LR3 mean it is an approved IGF-1 medicine?
No. A research analogue name cannot establish approval or interchangeability with a prescribed finished product.
Questions for your clinician
Does the evidence match my condition and this exact product? What risks or interactions matter for me? How would we assess whether it is helping?
Sources
- IGF-I variants which bind poorly to IGF-binding proteins show more potent and prolonged hypoglycaemic action than native IGF-I in pigs and marmoset monkeys1997 · Primary research · PubMed
- Compounding and the FDA: Questions and AnswersFDA · product quality and regulation
- AnaphylaxisMedlinePlus · recognizing an emergency
Educational information, not a recommendation to use a compound. Kairo does not give dosing advice. Review decisions with a licensed healthcare professional.